# Copper Peptide Hair Growth Research | GHK-Cu Follicle Studies > Copper Peptide Hair Growth Research: the 45-patient 5-ALA+GHK trial, the C3H-mouse follicle study, the dermal-papilla analog data, and what is and isn't proven for GHK-Cu — cited. The strongest human signal is a 45-patient trial of a 5-ALA + GHK combination — not pure GHK-Cu. The animal and mechanistic data, read with that caveat circled. ## What the copper peptide hair growth research shows Copper Peptide Hair Growth Research has one genuinely controlled human result and a supporting cast of animal and mechanistic studies — with a caveat that has to be circled every time. In a 6-month trial of 45 men with androgenetic alopecia, a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide (ALAVAX) increased hair count by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL versus 9.6 for placebo, with no adverse events in any group [4]. That is a statistically significant gain over placebo — and it is for a GHK-containing combination, not pure GHK-Cu. The rest of the [copper peptide hair growth research](/hair-research) rests on animal and mechanistic work. The honest summary is promise with a clear delivery and combination asterisk, read below claim by claim. The dose detail in the human trial is worth circling: the lower 50 mg/mL concentration outperformed the higher 100 mg/mL on hair count (71.5 versus 52.6 added hairs), which is a reminder that more concentrate is not the same as more effect, and that the trial tested a defined topical formulation rather than an open-ended regimen [4]. ## Do copper peptides stimulate hair growth? In a 6-month trial of 45 men with androgenetic alopecia, a 5-aminolevulinic-acid + glycyl-histidyl-lysine complex (ALAVAX) increased hair count by 52.6 (100 mg/mL) and 71.5 (50 mg/mL) versus 9.6 for placebo, with no adverse events [4]. Earlier work showed peptide-copper complexes stimulated hair-follicle activity in C3H mice [10]. The human trial used a combination, not pure GHK-Cu, so the strongest evidence is for the combination. ## Does copper peptide regrow hair? The strongest controlled human signal is the 45-patient ALAVAX (5-ALA + GHK) topical trial, which produced statistically significant hair-count gains over placebo across 6 months [4]. That evidence is for a GHK-containing combination rather than GHK-Cu alone, and broader copper-peptide hair claims rest largely on animal and mechanistic data [10]. So the literature supports regrowth for the combination and describes plausibility, not proof, for pure GHK-Cu. ## Does copper peptide work for hair growth? Research supports a plausible follicular mechanism — angiogenesis and dermal-papilla support — and one positive 6-month human RCT of a 5-ALA+GHK complex (n=45) [4]. Evidence specific to pure GHK-Cu in humans is limited, so the literature describes promise rather than an established treatment. A close copper-tripeptide analog, AHK-Cu, supports the mechanism in cell and ex-vivo models, but it is an analog, not GHK-Cu itself [14]. ## How long does GHK-Cu take to regrow hair? The 45-patient ALAVAX (5-ALA + GHK) trial measured hair-count gains over a 6-month course, and search engines summarize meaningful regrowth at roughly 3 months [4]. These are research timelines for a combination topical, not a dosing recommendation. No comparable timeline has been established for pure GHK-Cu in a controlled human hair-growth trial. ## Is copper a DHT blocker? No. The hair-follicle research on GHK-Cu describes a non-androgenic mechanism — Wnt/beta-catenin activation, dermal-papilla support, and angiogenesis — rather than inhibition of 5-alpha-reductase or dihydrotestosterone [6]. The copper peptide is not characterized in the literature as a DHT blocker. This matters for reading claims: a copper peptide and a DHT-pathway agent are doing different things, and conflating them oversells both. ## The proposed follicle mechanism The mechanistic case for copper peptides in hair sits on the same matrix and angiogenesis biology that drives the skin findings, redirected to the follicle. GHK-Cu upregulates VEGF and FGF-2 and chemoattracts repair and capillary cells, which is the angiogenic support a cycling follicle depends on, and it engages Wnt/beta-catenin signaling associated with the active growth (anagen) phase [6]. The copper ion's antioxidant behavior — full blockade of copper-dependent LDL oxidation in vitro — fits a tissue-protective rather than tissue-damaging role around the bulb [7]. None of this is androgen-pathway activity, which is why the literature does not describe the peptide as a finasteride-style agent [6]. The mechanism is plausible and partly demonstrated in cell and animal models; what it is not, yet, is proven follicle efficacy for pure GHK-Cu in a controlled human trial. The strongest human data remain the combination trial above, and the mechanism is the reason that result is biologically credible rather than a fluke [4][6]. ## The animal and analog evidence, read with caveats Below the human combination trial, the hair-growth case is preclinical. Peptide-copper complexes stimulated hair-follicle activity and growth in C3H mice — the foundational animal-model basis for copper peptides in hair research [10]. A close analog, AHK-Cu (the alanyl analog of GHK-Cu), at 10^-12 to 10^-9 M stimulated elongation of human hair follicles ex vivo and proliferation of dermal-papilla cells in vitro, and at 10^-9 M reduced apoptosis via an elevated Bcl-2/Bax ratio and lower cleaved caspase-3 [14]. Two caveats are circled here. First, the AHK-Cu data test the analog, not GHK-Cu, and should be read as mechanistic context only — never as GHK-Cu efficacy [14]. Second, the C3H-mouse work is an animal model. The mechanism is plausible and partly demonstrated; the human efficacy for pure GHK-Cu is not yet established. --- The GHK-Cu copper-peptide literature cut out and taped to one wall — each verified figure circled by hand, each inflated one struck through, and every missing stretch of human data marked in the margin, with no clinic pinned to this board and nothing here for sale.